Travel Vaccines Market Report 2026

The travel vaccines market size has grown strongly in recent years. It will grow from $5.09 billion in 2025 to $5.56 billion in 2026 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to limited access to vaccines in emerging markets, low public awareness of travel-related diseases, reliance on traditional vaccination centers, regulatory approvals for mono vaccines, slow adoption of online booking platforms.

The travel vaccines market size is expected to see rapid growth in the next few years. It will grow to $8.16 billion in 2030 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to increasing global travel and mobility, advancements in biotechnology for combination vaccines, growth of digital health and telemedicine services, rising awareness of preventive healthcare, expansion of international travel immunization programs. Major trends in the forecast period include rise in international tourism and business travel, increasing awareness of preventive healthcare for travelers, expansion of online travel health services and booking platforms, development of combination and multivalent travel vaccines, growth in public-private partnerships for global immunization programs.

The rising travel and tourism activity is expected to drive the growth of the travel vaccine market in the coming years. Travel and tourism involve the movement of people or goods, using vehicles such as airplanes, trains, and boats, across different geographic regions. Travel vaccines help protect tourists and travelers by providing immunity against infectious diseases prevalent in certain areas, ensuring safety and health while abroad. For instance, in May 2025, according to UN Tourism, a Spain-based specialized agency promoting responsible and sustainable tourism, over 300 million tourists traveled internationally in the first three months of 2025, approximately 14 million more than the same period in 2024, representing a 5% year-on-year increase. Consequently, the growth in global travel and tourism is contributing to the expansion of the travel vaccine market.

Leading companies in the travel vaccine market are developing innovative vaccines to provide active immunization against diseases like Hepatitis A, a common concern for travelers. Travel vaccines are specifically designed to protect individuals from region-specific infectious diseases and are recommended for travelers visiting affected areas. For example, in January 2024, Indian Immunologicals Ltd. (IIL), an India-based biotechnology company, launched Havisure, India’s first indigenously developed Hepatitis A vaccine. Havisure provides protection against the Hepatitis A virus, which primarily affects the liver, and is recommended for children as part of routine immunization, as well as for individuals at risk of exposure or traveling to high-prevalence regions.

In May 2023, Bavarian Nordic, a US-based biopharmaceutical company, acquired Emergent BioSolutions’ travel vaccine portfolio for an undisclosed amount. The acquisition included two commercially available vaccines - Vivotif for typhoid fever prevention and Vaxchora for cholera prevention - along with a Phase 3 vaccine candidate targeting the Chikungunya virus. It also encompassed US-based R&D facilities, a Swiss biologics production site, and EU and US commercial operations with a dedicated salesforce. Emergent BioSolutions, a US-based biotechnology company, specializes in the development and manufacture of devices, vaccines, therapeutics, and contract manufacturing, with travel vaccines as one of its business divisions.

Major companies operating in the travel vaccines market are Pfizer Inc, Johnson and Johnson, Merck & Co. Inc, Sanofi SA, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Serum Institute of India Pvt. Ltd., Bavarian Nordic A/S, Valneva SE, Panacea Biotec, Bharat Biotech International Limited, Bio Farma, Novavax Inc, Emergent BioSolutions UK, Biological E. Limited, Vabiotech, Cadila Healthcare Limited, Zydus Lifesciences Ltd, Cipla Inc, Haffkine Biopharmaceutical Corporation Ltd.

North America was the largest region in the travel vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the travel vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the travel vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the travel vaccines market by affecting the import and export of vaccine raw materials, adjuvants, and cold chain logistics equipment. The imposition of tariffs has increased manufacturing and distribution costs, particularly impacting combination vaccines and mono vaccines in regions like North America and Europe, where many raw materials are imported. While these tariffs pose challenges, they have encouraged local production and domestic vaccine manufacturing initiatives, which may strengthen regional supply chains and reduce dependence on international sources.

The travel vaccines market research report is one of a series of new reports that provides travel vaccines market statistics, including travel vaccines industry global market size, regional shares, competitors with a travel vaccines market share, detailed travel vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the travel vaccines industry. This travel vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Travel vaccines are immunizations designed to protect against diseases that are prevalent either in a traveler’s country of origin or their destination. They help safeguard travelers and prevent the spread of infections within and between countries.

The main travel vaccines include hepatitis A, diphtheria, pertussis, and tetanus (DPT), yellow fever, typhoid, hepatitis B, measles and mumps, rabies, meningococcal, and others. Hepatitis A is caused by the hepatitis A virus (HAV) and leads to liver inflammation. These vaccines are available as single vaccines or combination vaccines and can be accessed through online booking or in-person channels for domestic and international travel.

The travel vaccine market consists of sales of vaccines for diseases such as Japanese encephalitis, tick-borne encephalitis, and tuberculosis (TB). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.